Forest’s Faropenem Is “Not Approvable”; Additional Studies Will Take Two Years
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA decision reflects the agency's new position on the need for superiority studies to support the approval of antibiotics, Replidyne says.